Title of cohort


Quebec Longitudinal Study on Nutrition and Successful Aging

Acronym for cohort


NuAge

Name of Principal Investigator - Title


Prof

Name of Principal Investigator - First name


Hélène

Name of Principal Investigator - Last name


Payette

Address of institution -Institution


Centre de recherche sur le vieillissement

Address of institution - Street address


1036, rue Belvédère Sud

Address of institution - City


Sherbrooke

Address of institution - Postcode


J1H 4C4

Country


Canada

Website


www.maelstrom-research.org/mica/study/nuage

Contact email


[email protected]

Funding source


CIHR and the Quebec network for Research on aging

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?


Alzheimer's disease and other dementias

Q1b. When are studies on the above condition(s) expected to become possible?


Already possible

Q2a. In a single sentence what is the stated aim of the cohort?


Impact of Nutrition of cognitive decline and AD

Q2b. What distinguishes this cohort from other population cohorts?


Extensive data on nutrition, functional capacity, antropometry, gene polymorphism and serum biomarkers; biobank of serum, plasma, urine, saliva, DNA and RNA

Q3a. i) Number of publications that involve use of your cohort to date


45

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)


Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available


https://www.ncbi.nlm.nih.gov/pubmed/?term=NuAge+study

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population


Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:


68

Q4a. Study criteria: what is the age range of participants at recruitment? To:


82

Q4b. Study criteria: what are the inclusion criteria?


PMID: 17708689

Q4c. Study criteria: what are the exclusion criteria?


PMID: 17708689

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?


1,000-5,000 participants

Q6a. Please describe what measures are used to characterise participants


PMID: 17708689

Q6b. Are there additional measures for participants with a clinical disorder?


Specific cognitive domains

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?


If yes please specify


Q7. What is the study design (select all that apply)?


Longitudinal| Prospective cohort

Q8. Are your cases matched by


Q9a. Does your study include a specialised subset of control participants?


No

Q9b. If your study includes a specialised subset of control participants please describe


Q10a. i) Please enter the data collection start date


12/01/2003

Q10a. ii) Please enter the data collection end date


12/2009 + telelphoen interviews 2014-2015

Q10a. iii) Is data collection for this study


Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?


Q11. Is data collected


Only through the study

Other please specify here


Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?


Yes (participants given permission to be re-contacted via PIs)

Q13a. Please give information on the format and availability of data stored in a database (1)


Data summarised in database

% available


100

Q13a. Please give information on the format and availability of data stored in a database (2)


No

% available


Q13a. Please give information on the format and availability of data stored in a database (3)


No

% available


Q13a. Please give information on the format and availability of data stored in a database (4)


No

% available


Other (please specify)


% available


Q13b. Please give information on the format and availability of data held as individual records (1)


Data is held as individual records

% available


100

Q13b. Please give information on the format and availability of data held as individual records (2)


No

% available


Q13b. Please give information on the format and availability of data held as individual records (3)


Data held on computer based records

% available


100

Q13b. Please give information on the format and availability of data held as individual records (4)


No

% available


Please specify language used


French and English

Q14a. Is data available to other groups?


Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?


Apply to PI or co-ordinator at resource| Access committee mechanism|Local/ regional access| National Access| International Access| Access for pilot studies permitted| Applicant needs to provide separate external ethics approval| Proposal review

Q15. What data sharing policy is specified as a condition of use?


Q16a. Are tissues/samples/DNA available to other groups?


Yes

Q16b i) If yes, please describe below:


Living donors: blood derivatives| Living donors: DNA| Other (saliva, urin)

Q16b. ii) In what form are tissues/samples/DNA supplied?


Primary Samples: Stabilised samples (frozen or fixed)| Secondary samples: plasma| Secondary samples: DNA| Secondary samples: RNA

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?


Yes

Q17. Is information on biological characteristics available to other groups?


If available for a subset please specify number of patients and % of total cohort

Number of Patients


1300-1600

% of total cohort


75-90

Export as PDF